ProPhase Labs, Inc. (PRPH): Revenue
$4.34M
Year ended 2025-12-31
$3.85M
Trailing 12 months to 2026-06-30
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.34M | -35.8% | 2026-06-01, From 2025-01-01 |
| 2024-12-31 | $6.77M | -80.6% | 2026-06-01, From 2024-01-01 |
| 2023-12-31 | $34.98M | n/c | 2025-04-01, From 2023-01-01 |
| 2022-12-31 | $122.65M | +55.2% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $79.04M | +444.6% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $14.51M | +47.0% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $9.88M | -24.8% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $13.13M | +33.0% | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | $9.87M | +134.6% | 2019-03-26, From 2017-01-01 |
| 2016-12-31 | $4.21M | +67.0% | 2018-08-20, From 2016-01-01 |
| 2015-12-31 | $2.52M | -88.6% | 2018-08-20, From 2015-01-01 |
| 2014-12-31 | $22.07M | -11.8% | 2017-02-24, From 2014-01-01 |
| 2013-12-31 | $25.03M | +11.7% | 2016-03-29, From 2013-01-01 |
| 2012-12-31 | $22.41M | +28.4% | 2015-03-27, From 2012-01-01 |
| 2011-12-31 | $17.45M | +20.3% | 2014-03-27, From 2011-01-01 |
| 2010-12-31 | $14.50M | -26.8% | 2013-03-28, From 2010-01-01 |
| 2009-12-31 | $19.82M | n/a | 2012-03-07, From 2009-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $4.34M | -35.8% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $4.14M | -8.5% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.01M | -58.9% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $5.07M | -2.8% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $3.55M | -46.2% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $3.50M | +436.5% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $3.02M | +71.6% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $2.98M | +19.0% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $6.39M | +181.5% |
Compare PRPH, CPHI, CRVO, ENSC side by side · Screen every company in Pharmaceutical Preparations ↗